NASDAQ:ROIV

Roivant Sciences (ROIV) Stock Price, News & Analysis

Roivant Sciences logo
$38.61 -0.92 (-2.33%)
Closing price 04:00 PM Eastern
Extended Trading
$38.69 +0.08 (+0.22%)
As of 05:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Roivant Sciences Stock (NASDAQ:ROIV)

Advanced

Key Stats

Today's Range
$38.45
▼
$40.17
50-Day Range
$33.35
▼
$41.85
52-Week Range
$19.96
▼
$42.50
Volume
8.73 million shs
Average Volume
6.59 million shs
Market Capitalization
$27.89 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.82
Consensus Rating
Moderate Buy

Company Overview

Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases.

Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.

Roivant operates internationally, with activities spanning the United States and other markets. Matthew Gline is the company’s chief executive officer.

AI Generated. May Contain Errors.

Roivant Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

ROIV MarketRank™: 
2.303921568625 of 5 stars

Roivant Sciences scored higher than 46% of companies evaluated by MarketBeat, and ranked 624th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Roivant Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 1 strong buy rating, 10 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    Roivant Sciences has a consensus price target of $46.82, representing about 21.3% upside from its current price of $38.61.

  • Amount of Analyst Coverage

    Roivant Sciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Roivant Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Roivant Sciences are expected to decrease in the coming year, from ($2.00) to ($2.23) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Roivant Sciences is -61.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Roivant Sciences is -61.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Roivant Sciences has a P/B Ratio of 5.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.91% of the float of Roivant Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Roivant Sciences has a short interest ratio ("days to cover") of 6.07.
  • Change versus previous month

    Short interest in Roivant Sciences has recently increased by 12.93%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Roivant Sciences does not currently pay a dividend.

  • Dividend Growth

    Roivant Sciences does not have a long track record of dividend growth.

  • News Sentiment

    Roivant Sciences has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 21 news articles for Roivant Sciences this week, compared to 6 articles on an average week.
  • Search Interest

    Only 3 people have searched for ROIV on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
  • MarketBeat Follows

    Only 4 people have added Roivant Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Roivant Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $84,719,413.00 in company stock.

  • Percentage Held by Insiders

    8.80% of the stock of Roivant Sciences is held by insiders.

  • Percentage Held by Institutions

    64.76% of the stock of Roivant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Roivant Sciences' insider trading history.
Receive ROIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ROIV Stock News Headlines

My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
See More Headlines

ROIV Stock Analysis - Frequently Asked Questions

Roivant Sciences' stock was trading at $21.70 at the beginning of the year. Since then, ROIV stock has increased by 77.9% and is now trading at $38.61.

Roivant Sciences Ltd. (NASDAQ:ROIV) announced its quarterly earnings data on Friday, August, 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.30) by $0.04. The company earned $1.44 million during the quarter, compared to the consensus estimate of $2.06 million. Roivant Sciences had a negative trailing twelve-month return on equity of 22.03% and a negative net margin of 838.21%.
Read the conference call transcript
.

Top institutional shareholders of Roivant Sciences include State Street Corp (3.10%), Assenagon Asset Management S.A. (1.02%), Pictet Asset Management Holding SA (0.58%) and Candriam S.C.A. (0.24%). Insiders that own company stock include Sciences Ltd Roivant, Vivek Ramaswamy, Financial Lp Qvt, Mayukh Sukhatme, Matthew Gline, Frank Torti, Daniel Allen Gold, Keith S Manchester, Eric Venker, Richard Pulik, Rakhi Kumar, Jennifer Humes and Melissa B Epperly.
View institutional ownership trends
.

Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Roivant Sciences investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Palantir Technologies (PLTR), Broadcom (AVGO), Taiwan Semiconductor Manufacturing (TSM) and Energy Transfer (ET).

Company Calendar

Last Earnings
8/07/2026
Today
11/16/2026
Jefferies Global Healthcare Conference
11/17/2026
CMD 2026
12/09/2026
Fiscal Year End
3/31/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ROIV
CIK
1635088
Fax
N/A
Employees
721
Year Founded
2014

Price Target and Rating

High Price Target
$56.00
Low Price Target
$33.00
Potential Upside/Downside
+21.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.79
Research Coverage
14 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.63)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$299.77 million
Net Margins
-838.21%
Pretax Margin
-723.39%
Return on Equity
-22.03%
Return on Assets
-20.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
15.56
Quick Ratio
15.56

Sales & Book Value

Annual Sales
$41.08 million
Price / Sales
678.86
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.35 per share
Price / Book
5.25

Miscellaneous

Outstanding Shares
722,323,000
Free Float
660,800,000
Market Cap
$27.89 billion
Optionable
Optionable
Beta
1.23

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:ROIV) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners